Navigation Links
STALLERGENES: Persistent Efficacy Demonstrated After a Year on Actair(R) Followed by a Second Treatment-Free Year
Date:6/28/2010

rategic markets.

Oralair(R) is the first project resulting from this program. A Mutual Recognition Procedure has been completed in Europe. Having recently demonstrated its efficacy after 3 years of treatment (study VO53.06 conducted in Europe), Oralair(R) has been the subject of a positive phase III trial in adults in the United States (VO61.08).

The second project in the program is Actair(R), dust mite immunotherapy tablet. Following the results of the first year of the phase IIb/III study in allergic rhinitis in adults, a phase III pediatric study has been launched.

The Stalair(R) r Bet v 1 tablet (birch pollen recombinant allergen) has been the subject of a positive phase IIb/III clinical trial conducted in allergic rhinitis caused by birch pollen. A confirmatory phase III study is currently being prepared with a view to EMA registration.

The other allergens concerned by the program are ragweed pollen for the North American market and Japanese cedar pollen for the Japanese market. Altogether, the program covers 80% of the epidemiology for all markets.

ABOUT STALORAL(R) 300

Staloral(R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. It is indicated in the treatment of allergic rhinitis, rhinoconjunctivitis and seasonal or perennial mild to moderate allergic asthma in adults and children over the age of 5 years. Prescribed by allergy specialists, Staloral(R) 300 is particularly aimed at patients suffering from severe allergic diseases inadequately controlled by the use of symptomatic treatments.

In the context of a phase III clinical trial (VO55.06) conducted in

SOURCE Stallergenes
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study
2. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
3. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
4. FDA Approves New Device for Adults with Severe and Persistent Asthma
5. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
6. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
7. Study Analyzed SYMBICORT(R) in Children with Persistent Asthma
8. New Data Demonstrated Efficacy and Safety of Initial Combination Therapy with Welchol(R) (colesevelam HCl) and Metformin in Drug-Naive Adult Type 2 Diabetes Patients
9. New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects
10. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
11. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LONDON , December 24, 2014 ... to grow at an average rate of 8.1%. The ... volume. Hip, knee and spine surgeries are the common ... economies they have a lower penetration. Increased number of ... of composites. Non-metallic orthopedic devices have gained popularity in ...
(Date:12/24/2014)... 23, 2014  Advanced Medical Isotope Corporation ("AMIC") ... in the development of brachytherapy devices and medical ... that it has filed a de novo ... ("FDA") for marketing clearance for its patented Y-90 ... U.S. Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
...   ConvaTec, a world-leading developer and marketer of ... announced that it has acquired AbViser Medical, LLC (formerly ... City, UT-based company that specializes in products for the ... (IAP) Monitoring System enables clinicians to measure and monitor ...
... 1, 2012  Solta Medical, Inc. (NASDAQ: SLTM ), ... results for the first quarter ended March 31, 2012. Revenue ... $6.0 million, or 23%, as compared to the first quarter ... system, was $7.6 million, which was generated from sales of ...
Cached Medicine Technology:ConvaTec Announces Acquisition of AbViser Medical, LLC 2Solta Medical Reports First Quarter Results 2Solta Medical Reports First Quarter Results 3Solta Medical Reports First Quarter Results 4Solta Medical Reports First Quarter Results 5Solta Medical Reports First Quarter Results 6Solta Medical Reports First Quarter Results 7Solta Medical Reports First Quarter Results 8
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... The click strand woven bamboo ... durability. Today, the business announces a click strand ... Jan. 30, 2015. , Click strand woven bamboo ... is a well-known brand in the bamboo industry. ... a reliable bamboo flooring supplier. , “We are ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... Dec. 6 - Atlantic Information,Services, Inc. (AIS) -- ... Benefit News and Specialty Pharmacy News has just,released ... For the,past eight years, AIS has been surveying ... the results to track trends in this,volatile industry. ...
... do you get for the nut,that has everything, including more ... Chuck talking therapy doll?, You can at once give ... needs it, their own personal and portable psychotherapist. The,Ask Doctor ... which could,earn you the undying gratitude of the rest of ...
... ALISO VIEJO, Calif., Dec. 6 Clarient, Inc.,(Nasdaq: ... resource for,pathologists, oncologists and the pharmaceutical industry, today ... in a panel discussion,titled "From Discovery To Diagnosis: ... Capital Markets 2007 Healthcare Conference at 3:30 p.m.,EST ...
... Unveiled in Ongoing Preparation for Commercial Launch, ... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, ... that new data,including four-year follow-up data from ... (formerly FavId(R)), will be reported in four,separate ...
... and OMX Nordic Exchange: EPCT) today announced that ... overview at the New York Society,of Security Analysts ... December 12, 2007 at 4:05 p.m. Eastern Time. ... at 1177 Avenue of the Americas in,New York ...
... Be Presented at 2008 Convention, BALTIMORE, Dec. ... launched the Dr. Jacob Bolotin Award Program. Beginning ... present cash awards to,individuals and organizations that have ... the blind into society on a basis,of equality., ...
Cached Medicine News:Health News:2000-2007 Pharmacy Benefit Survey Results Just Released 2Health News:The Cure for Holiday Stress 2Health News:Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 3Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 4Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 5Health News:EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference 2Health News:EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference 3Health News:National Federation of the Blind to Award $100,000 2
... Accu-Temp Cauteries provide a broad selection ... a wide variety of ophthalmic procedures. ... sterile, complete with a safety cap ... " position when not in use, ...
... a broad selection of tip styles ... of ophthalmic procedures. Each single use ... a safety cap to lock switch ... not in use, and carries a ...
... provide the surgeon with an indirect illumination ... be easily visualized through the laser microscope. ... light scatter technique, the surgeon can enhance ... edge folds, corneal flap striae and flap ...
... system allows you access to the most ... system includes 10 different optotypes, crowding bars, ... characters. Random character sequencing eliminates memorization. In ... line and multiple line selection capability. The ...
Medicine Products: